CalciMedica Secures $49 Million Financing to Advance Pulmonary Hypertension Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: PRnewswire
- Financing Details: CalciMedica has entered into a definitive securities purchase agreement for a private placement expected to raise approximately $49 million, primarily aimed at advancing its CRAC channel inhibition strategy for pulmonary arterial hypertension (PAH), with a Phase 1b study anticipated in mid-2027.
- Clinical Trial Plans: The company intends to conduct a capital-efficient Phase 1b proof-of-concept study evaluating Auxora™, its intravenous CRAC channel inhibitor, in PAH patients, aiming to generate early human evidence for CRAC channel inhibition in pulmonary hypertension.
- Market Potential and Strategic Importance: PAH represents a multi-billion-dollar market, and CalciMedica's CRAC channel inhibitors are positioned to potentially be the first therapy providing direct right ventricular support and anti-remodeling activity, addressing significant unmet needs in the market.
- Safety and Development Outlook: Auxora has been evaluated in over 350 patients, demonstrating a favorable safety profile that supports its continued development across the pulmonary hypertension program and other indications, which is expected to provide robust support for the company's future clinical research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CALC
Wall Street analysts forecast CALC stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.988
Low
20.00
Averages
20.00
High
20.00
Current: 0.988
Low
20.00
Averages
20.00
High
20.00
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adobe and CalciMedica Executives Increase Stock Holdings
- Adobe Executive Purchase: On Thursday, Adobe's Director David A. Ricks purchased 10,000 shares of ADBE at $194.51 each, totaling $1.95 million, indicating strong confidence in the company's future performance, with a peak gain of 7.5% during the trading session.
- Stock Price Fluctuation: On Monday, ADBE's stock reached a high of $209.13, reflecting a significant increase from Thursday's purchase price, contributing to a 2.9% rise in the stock on that day, showcasing positive market sentiment towards Adobe.
- CalciMedica Purchase Details: Also on Thursday, Fred A. Middleton acquired 248,972 shares of CalciMedica at $0.80 each, totaling nearly $200,000, signaling optimism about the company's prospects, with CalciMedica's stock rising approximately 4% on Monday.
- Market Reaction Analysis: The insider purchases by both executives not only reflect their confidence in the future growth of their respective companies but may also create a positive ripple effect among investors, increasing market interest and investment in both Adobe and CalciMedica.
See More
CalciMedica Secures $49 Million Financing to Advance Pulmonary Hypertension Strategy
- Financing Details: CalciMedica has entered into a definitive securities purchase agreement for a private placement expected to raise approximately $49 million, primarily aimed at advancing its CRAC channel inhibition strategy for pulmonary arterial hypertension (PAH), with a Phase 1b study anticipated in mid-2027.
- Clinical Trial Plans: The company intends to conduct a capital-efficient Phase 1b proof-of-concept study evaluating Auxora™, its intravenous CRAC channel inhibitor, in PAH patients, aiming to generate early human evidence for CRAC channel inhibition in pulmonary hypertension.
- Market Potential and Strategic Importance: PAH represents a multi-billion-dollar market, and CalciMedica's CRAC channel inhibitors are positioned to potentially be the first therapy providing direct right ventricular support and anti-remodeling activity, addressing significant unmet needs in the market.
- Safety and Development Outlook: Auxora has been evaluated in over 350 patients, demonstrating a favorable safety profile that supports its continued development across the pulmonary hypertension program and other indications, which is expected to provide robust support for the company's future clinical research.
See More
FDA Reviews CalciMedica's KOURAGE Trial Protocol Amendment
- FDA Review Progress: The FDA has reviewed CalciMedica's protocol amendment and interim safety data for the KOURAGE trial without any comments, confirming the company's ability to continue dosing patients with Auxora in the study, thereby ensuring the continuity of clinical development.
- Trial Enrollment Pause: In January 2026, CalciMedica paused enrollment in the KOURAGE trial due to safety concerns regarding mortality imbalance raised by the Independent Data Monitoring Committee, although no drug-related toxicity was identified, demonstrating the company's strong commitment to patient safety.
- Protocol Amendment Details: The protocol amendment submitted by CalciMedica in March 2026 included refinements to patient inclusion criteria and changes to stratification methodology, aimed at addressing design issues and ensuring the scientific validity and efficacy of the trial.
- Future Outlook: CalciMedica expects to receive feedback from the FDA in the third quarter of 2026 regarding the design of a potential pivotal program evaluating Auxora in acute pancreatitis, further advancing its clinical development plans.
See More
CalciMedica Secures $49 Million Financing for Pulmonary Hypertension Strategy
- Financing Details: CalciMedica has entered into a definitive securities purchase agreement for a private placement expected to raise approximately $49 million, including $15 million in upfront proceeds, reflecting strong investor confidence in its pulmonary hypertension (PH) strategy.
- Clinical Trial Plans: The company plans to conduct a Phase 1b proof-of-concept study for Auxora™ in mid-2027, aimed at providing early human evidence for CRAC channel inhibition in pulmonary arterial hypertension (PAH), thereby de-risking the development of CM5480.
- Market Opportunity: PAH represents a multi-billion-dollar market, and CalciMedica's CRAC channel inhibitors are positioned to potentially be the first therapy to provide direct right ventricular support and anti-remodeling activity, addressing significant unmet medical needs in this area.
- Safety Profile: Auxora has demonstrated a favorable safety profile in over 350 patients across clinical trials, supporting its continued development in the PH program and other indications, which is expected to bolster the company's future product pipeline.
See More
CalciMedica Receives FDA Review of KOURAGE Trial Progress
- FDA Review Outcome: CalciMedica's KOURAGE trial for acute kidney injury has received FDA review with no comments, indicating that the company can continue dosing patients with Auxora in the study, ensuring the continuity of clinical development.
- Trial Enrollment Pause: In January 2026, CalciMedica paused enrollment in the KOURAGE trial due to safety concerns raised by the Independent Data Monitoring Committee, although no drug-related toxicity was identified, necessitating a reevaluation of the study design to address imbalances in baseline disease severity among patients.
- Protocol Amendment Submission: In March 2026, CalciMedica submitted a protocol amendment for the KOURAGE trial, refining patient inclusion criteria and changing stratification methods, ensuring a comprehensive safety assessment of 107 patients dosed prior to the enrollment pause, with no drug-related serious adverse events identified.
- Future Outlook: CalciMedica expects to receive FDA feedback on the design of a potential pivotal program evaluating Auxora in acute pancreatitis in the third quarter of 2026, further advancing its clinical development plans.
See More
CalciMedica Reports Q1 2026 Financial Results with Significant Income Growth
- Earnings Performance: CalciMedica reported a Q1 2026 GAAP EPS of -$0.30, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of March 31, 2026, the company held $8.2 million in cash and cash equivalents, which is expected to sufficiently fund its operating plan into Q4 2026, reflecting a relatively stable liquidity management in the short term.
- Significant Income Growth: Other income surged to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, an increase of $9.1 million primarily due to fair value adjustments on promissory notes and common stock warrants, indicating improved asset management.
- Financial Outlook: Despite the negative EPS, the substantial growth in cash flow and other income may lay the groundwork for future financial recovery, prompting investors to monitor the company's strategic adjustments and market responses closely.
See More
Adobe and CalciMedica Executives Increase Stock Holdings
- Adobe Executive Purchase: On Thursday, Adobe's Director David A. Ricks purchased 10,000 shares of ADBE at $194.51 each, totaling $1.95 million, indicating strong confidence in the company's future performance, with a peak gain of 7.5% during the trading session.
- Stock Price Fluctuation: On Monday, ADBE's stock reached a high of $209.13, reflecting a significant increase from Thursday's purchase price, contributing to a 2.9% rise in the stock on that day, showcasing positive market sentiment towards Adobe.
- CalciMedica Purchase Details: Also on Thursday, Fred A. Middleton acquired 248,972 shares of CalciMedica at $0.80 each, totaling nearly $200,000, signaling optimism about the company's prospects, with CalciMedica's stock rising approximately 4% on Monday.
- Market Reaction Analysis: The insider purchases by both executives not only reflect their confidence in the future growth of their respective companies but may also create a positive ripple effect among investors, increasing market interest and investment in both Adobe and CalciMedica.
See More
CalciMedica Secures $49 Million Financing to Advance Pulmonary Hypertension Strategy
- Financing Details: CalciMedica has entered into a definitive securities purchase agreement for a private placement expected to raise approximately $49 million, primarily aimed at advancing its CRAC channel inhibition strategy for pulmonary arterial hypertension (PAH), with a Phase 1b study anticipated in mid-2027.
- Clinical Trial Plans: The company intends to conduct a capital-efficient Phase 1b proof-of-concept study evaluating Auxora™, its intravenous CRAC channel inhibitor, in PAH patients, aiming to generate early human evidence for CRAC channel inhibition in pulmonary hypertension.
- Market Potential and Strategic Importance: PAH represents a multi-billion-dollar market, and CalciMedica's CRAC channel inhibitors are positioned to potentially be the first therapy providing direct right ventricular support and anti-remodeling activity, addressing significant unmet needs in the market.
- Safety and Development Outlook: Auxora has been evaluated in over 350 patients, demonstrating a favorable safety profile that supports its continued development across the pulmonary hypertension program and other indications, which is expected to provide robust support for the company's future clinical research.
See More
FDA Reviews CalciMedica's KOURAGE Trial Protocol Amendment
- FDA Review Progress: The FDA has reviewed CalciMedica's protocol amendment and interim safety data for the KOURAGE trial without any comments, confirming the company's ability to continue dosing patients with Auxora in the study, thereby ensuring the continuity of clinical development.
- Trial Enrollment Pause: In January 2026, CalciMedica paused enrollment in the KOURAGE trial due to safety concerns regarding mortality imbalance raised by the Independent Data Monitoring Committee, although no drug-related toxicity was identified, demonstrating the company's strong commitment to patient safety.
- Protocol Amendment Details: The protocol amendment submitted by CalciMedica in March 2026 included refinements to patient inclusion criteria and changes to stratification methodology, aimed at addressing design issues and ensuring the scientific validity and efficacy of the trial.
- Future Outlook: CalciMedica expects to receive feedback from the FDA in the third quarter of 2026 regarding the design of a potential pivotal program evaluating Auxora in acute pancreatitis, further advancing its clinical development plans.
See More
CalciMedica Secures $49 Million Financing for Pulmonary Hypertension Strategy
- Financing Details: CalciMedica has entered into a definitive securities purchase agreement for a private placement expected to raise approximately $49 million, including $15 million in upfront proceeds, reflecting strong investor confidence in its pulmonary hypertension (PH) strategy.
- Clinical Trial Plans: The company plans to conduct a Phase 1b proof-of-concept study for Auxora™ in mid-2027, aimed at providing early human evidence for CRAC channel inhibition in pulmonary arterial hypertension (PAH), thereby de-risking the development of CM5480.
- Market Opportunity: PAH represents a multi-billion-dollar market, and CalciMedica's CRAC channel inhibitors are positioned to potentially be the first therapy to provide direct right ventricular support and anti-remodeling activity, addressing significant unmet medical needs in this area.
- Safety Profile: Auxora has demonstrated a favorable safety profile in over 350 patients across clinical trials, supporting its continued development in the PH program and other indications, which is expected to bolster the company's future product pipeline.
See More
CalciMedica Receives FDA Review of KOURAGE Trial Progress
- FDA Review Outcome: CalciMedica's KOURAGE trial for acute kidney injury has received FDA review with no comments, indicating that the company can continue dosing patients with Auxora in the study, ensuring the continuity of clinical development.
- Trial Enrollment Pause: In January 2026, CalciMedica paused enrollment in the KOURAGE trial due to safety concerns raised by the Independent Data Monitoring Committee, although no drug-related toxicity was identified, necessitating a reevaluation of the study design to address imbalances in baseline disease severity among patients.
- Protocol Amendment Submission: In March 2026, CalciMedica submitted a protocol amendment for the KOURAGE trial, refining patient inclusion criteria and changing stratification methods, ensuring a comprehensive safety assessment of 107 patients dosed prior to the enrollment pause, with no drug-related serious adverse events identified.
- Future Outlook: CalciMedica expects to receive FDA feedback on the design of a potential pivotal program evaluating Auxora in acute pancreatitis in the third quarter of 2026, further advancing its clinical development plans.
See More
CalciMedica Reports Q1 2026 Financial Results with Significant Income Growth
- Earnings Performance: CalciMedica reported a Q1 2026 GAAP EPS of -$0.30, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Position: As of March 31, 2026, the company held $8.2 million in cash and cash equivalents, which is expected to sufficiently fund its operating plan into Q4 2026, reflecting a relatively stable liquidity management in the short term.
- Significant Income Growth: Other income surged to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, an increase of $9.1 million primarily due to fair value adjustments on promissory notes and common stock warrants, indicating improved asset management.
- Financial Outlook: Despite the negative EPS, the substantial growth in cash flow and other income may lay the groundwork for future financial recovery, prompting investors to monitor the company's strategic adjustments and market responses closely.
See More
